GettyImages-932533514-hero

Cancer Center

Cancer Research Funding

Current Funding Opportunities

MCW Cancer Center Pilot Funding Program

Grant support resources are now available from the MCW Cancer Center.




 

National Cancer Institute (NCI)

Testing Interventions for Health-Enhancing Physical Activity (R01 - Clinical Trial Optional)

The purpose of this Funding Opportunity Announcement (FOA) is to fund highly innovative and promising research that tests multi-level physical activity intervention programs acting on at least two levels of the socio-ecological model and designed to increase health-enhancing physical activity: 1) in persons or groups that can benefit from such activity; and 2) that could be made scalable and sustainable for broad use across the nation. This FOA provides support for up to 5 years for research planning, intervention delivery, and follow-up activities.

Applications due October 5, 2018; June 5, 2019; February 5, 2020; and October 5, 2020

 

Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH3) Clinical Trials Not Allowed

The purpose of this Funding Opportunity Announcement (FOA) is to accelerate the adoption and validation of molecular/cellular/imaging markers and assays for cancer detection, diagnosis, prognosis, monitoring, and prediction of response or resistance to treatment, as well as markers for cancer prevention and control. This FOA also includes the validation of pharmacodynamic markers and markers of toxicity. Applicants to this FOA must have an assay(s) whose performance has been analytically validated in specimens similar to those for the intended clinical use of the assay(s) and marker(s). As chemotherapies and/or radiation therapies are increasingly combined with immunotherapies to enhance durability of anti-cancer responses, multiple assays for measuring multiple markers, including immune markers, can be developed and validated simultaneously.

Applications due February 14, 2018; July 10, 2018; October 8, 2018

 

National Institutes of Health (NIH)

SBIR Phase IIB Bridge Awards to Accelerate the Development of Cancer-Relevant Technologies Toward Commercialization (R44 Clinical Trial Optional)

This Funding Opportunity Announcement (FOA) solicits Small Business Innovation Research (SBIR) applications from small business concerns (SBCs) that seek additional funding to support the next stage of development for cancer-relevant projects that were previously funded under SBIR or STTR Phase II awards from any Federal agency. The purpose of this FOA is to facilitate the transition of SBIR or STTR Phase II projects to the commercialization stage.

This FOA is expected to promote partnerships between Federally-funded SBIR or STTR Phase II awardees and third-party investors and/or strategic partners to facilitate and accelerate the capital-intensive steps that are required to commercialize new products and services. Applicants must submit a Commercialization Plan, which should include details on any independent third-party investor funding that has already been secured or is anticipated during the Phase IIB Bridge Award project period. It is expected that the level of this independent third-party funding will be equal to or greater than the NCI funds being requested throughout the Phase IIB Bridge Award project period. Proposed projects may address preclinical and/or clinical stages of technology development. Clinical trials may be proposed as appropriate but are not required.

Deadline: August 15, 2018

 

Investigation of the Transmission of Kaposi Sarcoma-Associated Herpesvirus (KSHV) (R01/R21 Clinical Trial Not Allowed)

The purpose of the funding opportunity announcement (FOA) is to advance our understanding of the modes of transmission of Kaposi sarcoma-associated herpesvirus (KSHV), also called human herpesvirus-8 (HHV-8); the biology of the initial steps of infection; and risk factors for infection to inform efforts to prevent KSHV transmission and thus prevent Kaposi sarcoma (KS), KSHV-associated multicentric Castleman disease (MCD), primary effusion lymphoma (PEL), and other KSHV-induced diseases in populations living with HIV or at high risk of developing HIV.

This program covers two parallel FOAs of identical scientific scope. This FOA solicits applications for exploratory/developmental projects using the NIH R21 mechanism. The companion FOA, RFA-CA-18-013, is a parallel announcement for well-developed research projects using the NIH R01 funding mechanism.

Deadline: August 16, 2018


Cooperative Human Tissue Network (CHTN) (UM1 Clinical Trial Not Allowed)

The purpose of this Funding Opportunity Announcement (FOA), issued by the National Cancer Institute (NCI), is to support the Cooperative Human Tissue Network (CHTN). The goal for CHTN is to collect and distribute to investigators high quality human tissue specimens to facilitate basic and early translational cancer research. For example, such specimens may be needed for scientific discovery and the development of various molecular diagnostic tests, prognostic or predictive assays. The CHTN is designed as a unique biospecimen resource in that it is based on prospective collection and distribution of samples upon specific investigators' requests. Samples to be collected from patients include pre-cancerous, cancerous, and benign neoplastic tissues, as well as specimens corresponding to non-neoplastic diseases and uninvolved tissues.

This FOA solicits applications for CHTN awards from institutions/teams capable of contributing to the mission of CHTN by: (1) providing prospective investigator-defined procurement of high-quality malignant, benign, diseased, and uninvolved (normal adjacent) tissues and fluids from patients throughout North America and elsewhere; (2) assisting individual investigators with regard to specific specimen needs of their research; (3) assisting in developing and disseminating knowledge on high quality practices for successfully operating a biospecimen repository; and (4) educating the community about the importance of the availability of high quality human tissue specimens for medical research. Depending on their intentions and capabilities, applicants must indicate whether they propose to function as the CHTN adult biospecimen division or the pediatric specimen division. Nonetheless, it will be acceptable for an adult biospecimen division, if capable, to contribute pediatric samples for networked requests.

Deadline: August 28, 2018 (LOI due July 28, 2018)

 

Cooperative Human Tissue Network (CHTN) (UM1 Clinical Trial Not Allowed)-LIMITED SUBMISSION*

The purpose of this Funding Opportunity Announcement (FOA), issued by the National Cancer Institute (NCI), is to support the Cooperative Human Tissue Network (CHTN). The goal for CHTN is to collect and distribute to investigators high quality human tissue specimens to facilitate basic and early translational cancer research. For example, such specimens may be needed for scientific discovery and the development of various molecular diagnostic tests, prognostic or predictive assays. The CHTN is designed as a unique biospecimen resource in that it is based on prospective collection and distribution of samples upon specific investigators' requests. Samples to be collected from patients include pre-cancerous, cancerous, and benign neoplastic tissues, as well as specimens corresponding to non-neoplastic diseases and uninvolved tissues.

This FOA solicits applications for CHTN awards from institutions/teams capable of contributing to the mission of CHTN by: (1) providing prospective investigator-defined procurement of high-quality malignant, benign, diseased, and uninvolved (normal adjacent) tissues and fluids from patients throughout North America and elsewhere; (2) assisting individual investigators with regard to specific specimen needs of their research; (3) assisting in developing and disseminating knowledge on high quality practices for successfully operating a biospecimen repository; and (4) educating the community about the importance of the availability of high quality human tissue specimens for medical research. Depending on their intentions and capabilities, applicants must indicate whether they propose to function as the CHTN adult biospecimen division or the pediatric specimen division. Nonetheless, it will be acceptable for an adult biospecimen division, if capable, to contribute pediatric samples for networked requests.

Deadline:

  • LOI due July 23, 2018
  • Application due August 28, 2018

*Due to this being a limited submission, LOI’s are due to Nicole Davis nmdavis@mcw.edu no later than noon on July 23.  The selected LOI will be chosen and PI notified no later than July 30, 2018. 

 

NCI Community Oncology Research Program (NCORP) Research Bases (UG1 Clinical Trial Required)

This Funding Opportunity Announcement (FOA) solicits applications from institutions/organizations to participate as "Research Bases" for the National Cancer Institute (NCI)-supported Community Oncology Research Program (NCORP). NCORP is a community-based research network that:

  • Designs and conducts clinical trials and other human subject studies for adults and children in cancer prevention, control, screening, and care delivery, as well as quality-of-life studies embedded within treatment trials;
  • Incorporates unique research needs of diverse populations such as, adolescents and young adults (AYAs), and the elderly; racial and ethnic minorities; sexual and gender minorities; and rural residents into studies and takes steps to enhance participation of these groups;
  • Enhances patient and provider access to treatment and imaging trials conducted under the National Clinical Trials Network (NCTN);
  • Integrates cancer disparities research within the community network.

NCORP consists of three components each with its own FOA: NCORP Research Bases (covered by this FOA); NCORP Community Sites; and NCORP Minority/Underserved Community Sites.

The NCORP Research Bases will design and conduct cancer clinical trials and care delivery research studies as well as manage and analyze the data and report the research results.

Deadline: August 31, 2018

   

NCI Community Oncology Research Program (NCORP) Minority/Underserved Community Sites (UG1 Clinical Trial Required)

This Funding Opportunity Announcement (FOA) solicits applications from institutions/organizations to participate as "Minority/Underserved Community Sites" for the National Cancer Institute (NCI)-supported Community Oncology Research Program (NCORP). NCORP is a community-based research network that:

  • Designs and conducts clinical trials and other human subject studies for adults and children in cancer control, prevention, screening, and care delivery, as well as quality-of-life studies embedded within treatment trials;
  • Incorporates the needs of diverse populations such as, adolescents and young adults (AYAs), and the elderly; racial and ethnic minorities; sexual and gender minorities; and rural residents into studies and takes steps to enhance participation of these groups;
  • Enhances patient and provider access to treatment and imaging trials conducted under the National Clinical Trials Network (NCTN);
  • Integrates cancer disparities research within the community network.

NCORP consists of three components each with its own FOA: NCORP Research Bases; NCORP Community Sites; and NCORP Minority/Underserved Community Sites (covered by this FOA).

The NCORP Minority/Underserved Community Sites will accrue diverse patients/participants to NCI-approved, cancer control, prevention, and care delivery research studies designed by NCI's NCORP Research Bases as well as treatment trials within the National Clinical Trials Network Groups (NCTN).

Deadline: August 31, 2018

 

Cancer Prevention, Diagnosis, and Treatment Technologies for Low-Resource Settings (R43/R44/R41/R42 - Clinical Trial Optional)

This Funding Opportunity Announcement (FOA) encourages Small Business Innovation Research (SBIR) grant applications from small business concerns (SBCs) proposing commercially-directed research for the development of cancer prevention, diagnosis, or treatment technologies to improve cancer outcomes in low- and middle-income countries (LMICs), and low-resource settings in the US. Specifically, the FOA encourages grant applications from SBCs to develop or adapt, apply, and validate existing or emerging technologies into user-friendly products for cancer prevention, diagnosis, or treatment in low-resource settings. These technologies should be practical and affordable in the low-resource settings, including remote or underserved populations within or outside the US. The technologies may include, but are not limited to tools for vaccine dissemination/delivery, imaging, in vitro diagnosis, or treatment of pre-cancerous (pre-neoplastic) or cancerous lesions that are preventable or treatable within low-resource settings. Strong emphasis is placed on technologies that directly provide or immediately lead to treatment options available in the local health system.

Deadline: September 5, 2018

 

The purpose of this trans-NCI Funding Opportunity Announcement (FOA) is to promote new cancer disparities research among investigators who do not normally conduct it and to encourage the partnership of experienced cancer research investigators with cancer disparities-focused researchers. This FOA is intended to accelerate and strengthen multi-disciplinary cancer disparities research in wide ranging areas. Cancer disparities research includes, but is not limited to basic, translational, behavioral, observational, interventional, environmental and population research studies that address the adverse differences in cancer incidence, prevalence, mortality, survivorship, burden and/or response to treatment in racial/ethnic minorities and/or underserved population groups. Proposed collaborations should focus on achieving research objectives that by necessity rely on diverse and complementary expertise, technical capabilities, and resource sets. Importantly, the supplemental request is required to be within the scope of the parent award and should expand the original aims to include a cancer disparity component.

Deadline: September 10, 2018

 

Bioengineering Research Partnerships (U01 Clinical Trial Optional)

This Funding Opportunity Announcement (FOA) encourages bioengineering applications that will accelerate the development and adoption of promising tools and technologies that can address important biomedical problems.  The objectives are to establish these tools and technologies as robust, well-characterized solutions that fulfill an unmet need and are capable of enhancing our understanding of life science processes or the practice of medicine.  Awards will focus on supporting multidisciplinary teams that apply an integrative, quantitative bioengineering approach to developing technologies, and engage biomedical researchers or clinicians throughout the project.  The goal of the program is to support projects that can realize meaningful solutions within 5 – 10 years.

Deadline:

  • May 8, 2018
  • September 13, 2018
   

Improving the Reach and Quality of Cancer Care in Rural Populations (R01 Clinical Trial Required)

The purpose of this Funding Opportunity Announcement (FOA) is to reduce the burden of cancer and improve the quality of cancer care in rural areas among low-income and/or underserved populations.

The FOA encourages two types of applications: 1) observational research that includes pilot testing of intervention to understand and address predictors of cancer care/treatment and outcomes in rural low-income and/or underserved populations; or 2) intervention research to address known predictors of cancer care/treatment and outcomes in rural low-income and/or underserved populations.Specifically, the focus for observational studies (with pilot testing) is understanding and addressing the predictive and/or mediating role of social determinants of health, barriers to care, and treatment; and the focus for interventional research is on addressing quality of care related to cancer diagnosis, treatment and/or survivorship. Most existing cancer control interventions are not ready for direct implementation and dissemination in low-income rural areas, so proposals should seek to develop, adapt, and/or implement, and test interventions.

Deadline: Due September 19, 2018

   

Revisions for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research

The purpose of this Funding Opportunity Announcement (FOA) is to encourage revision applications to incorporate a new technical approach or instrument developed through support from the NCI Innovative Molecular Analysis Technologies (IMAT) program from currently funded grant (see options below). Awards from this FOA are meant to incentivize independent validation and accelerate the suitability of these emerging technologies for appropriate research communities.

As a component of the NCI IMAT program, this FOA aims to promote interdisciplinary collaboration in the development of innovative tools and methods that enable cancer research and accelerate scientific discovery.

Application Due: February 28, 2018; May 29, 2018; and September 28, 2018

Innovations for Healthy Living - Improving Minority Health and Eliminating Health Disparities (R43/R44 - Clinical Trial Optional)

This Funding Opportunity Announcement (FOA) invites eligible United States small business concerns (SBCs) to submit Small Business Innovation Research (SBIR) grant applications that propose to develop a product, process or service for commercialization with the aim of improving minority health and/or reducing health disparities in one or more NIH-defined health disparity population groups. Appropriate technologies should be effective, affordable, and culturally acceptable.

Deadline: October 1, 2018

   

Technologies for Improving Minority Health and Eliminating Health Disparities (R41/R42- Clinical Trial Optional)

This Funding Opportunity Announcement (FOA) invites eligible United States small business concerns (SBCs) to submit Small Business Technology Transfer (STTR) grant applications that propose to develop a product, process or service for commercialization with the aim of improving minority health and/or reducing health disparities in one or more NIH-defined health disparity population groups. Appropriate technologies should be effective, affordable, and culturally acceptable.

Deadline: October 1, 2018

   

Novel Genomic Technology Development (R01/R21 Clinical Trial Not Allowed)

This Funding Opportunity Announcement (FOA) seeks grant applications to catalyze major advances in genomics through technology development (beyond developing nucleic acid sequencing technologies). The goal is to provide a mechanism for support of very novel and high impact work from across this gamut of genomics technology development. This initiative seeks to support technologies that will have a major impact in the next five to seven years.

Deadline: October 2, 2018

   

Advancing Mechanistic Probiotic/Prebiotic and Human Microbiome Research (R01 Clinical Trial Not Allowed)

The purpose of this funding opportunity announcement (FOA) is twofold: (1) to stimulate basic and mechanistic science that facilitates the development of effective probiotics or pre-/probiotic combinations of relevance to human health and disease; and (2) determine biological outcomes for the evaluation of efficacy of pre/probiotics in appropriate test systems and animal models. This FOA encourages basic and mechanistic studies using in vitro, in vivo, ex vivo, and in silico models that focus on prebiotic/probiotic strain selectivity, interaction, and function. It will also encourage inter and multidisciplinary collaborations among scientists in a wide range of disciplines including nutritional science, immunology, microbiomics, genomics, other '-omic' sciences, biotechnology, and bioinformatics.

Deadline: October 5, 2018

   

Harnessing Big Data to Halt HIV (R01 Clinical Trial Optional)

The purpose of this Funding Opportunity Announcement (FOA) is to promote research that transforms understanding of HIV transmission, the HIV care continuum, and HIV comorbidities using Big Data Science (BDS). This FOA will support projects to assemble diverse big data sources, conduct robust and reproducible analyses, and create meaningful visualizations of big data, as well as, engage ethical experts where appropriate to ensure the development of this scientific area is guided by ethical principles.

Deadline: Due October 5, 2018

 

Metabolic Reprogramming to Improve Immunotherapy (R01)

The overall goal of this funding opportunity announcement (FOA) is to encourage R01 grant applications to (a) generate a mechanistic understanding of the metabolic processes that support robust anti-tumor immune responses in vivo, (b) determine how the metabolic landscape of the tumor microenvironment affects immune effector functions, and (c) then use this information to manipulate (reprogram) the metabolic pathways used by the tumor, the immune response, or both to improve cancer immunotherapy.

Deadline: June 5, 2018 OR October 5, 2018

 

Precision Imaging of Oral Lesions (R01- Clinical Trial Not Allowed)

The intent of this Funding Opportunity Announcement (FOA) is to advance the development, adaptation, optimization, and validation of accurate, reproducible, specific, and sensitive imaging approaches to improve diagnosis, treatment, and treatment monitoring for diseases and conditions in the oral cavity and oropharynx. 

Deadline: October 5, 2018

   

The Role of Mobile Genetic Elements in Cancer (R01)

The overall goal of this funding opportunity announcement (FOA) is to encourage applications to investigate mechanisms regulating the expression and activity of mobile genetic elements, including long terminal repeat (LTR) and non-LTR retroelements, in cancer. For example, although long interspersed element-1 (LINE-1 or L1) retroelements are active in many cancers whether somatic L1 insertions lead to cancer cell heterogeneity and/or adaptive phenotypes that confer growth or survival advantages during cancer evolution or response to therapy is not clear. Similarly, how human endogenous viruses (HERVs) affect cancer processes is also not well understood. In an effort to address this knowledge gap, this FOA invites research applications that specifically investigate mechanisms regulating the expression and activity of mobile genetic elements in the context of cell transformation and assess the impact of their activity on tumor heterogeneity, cancer evolution, and response to therapy.

Deadline: June 5, 2018 OR October 5, 2018

   

Early Phase Clinical Trials in Imaging and Image-Guided Interventions (R01 Clinical Trial Required)

This Funding Opportunity Announcement (FOA) is intended to support clinical trials conducting preliminary evaluation of the safety and efficacy of imaging agents, as well as an assessment of imaging systems, image processing, image-guided planning and/or execution therapy, contrast kinetic modeling, 3-D reconstruction and other quantitative tools. As many such preliminary evaluations are early in development, this FOA will provide investigators with support for pilot (Phase I and II) cancer imaging clinical trials, including patient monitoring and laboratory studies. This FOA supports novel uses of known/standard clinical imaging agents and methods as well as the evaluation of new agents, systems, or methods. The imaging and image-guided intervention (IGI) investigations, if proven successful in these early clinical trials, can then be validated in larger studies through competitive R01 mechanisms, or through clinical trials in the Specialized Programs of Research Excellence (SPOREs), Cancer Centers and/or the NCI's National Clinical Trials Network.

Deadline:

  • February 14, 2018
  • June 28, 2018
  • October 11, 2018
   

Program to Assess the Rigor and Reproducibility of Exosome-Derived Analytes for Cancer Detection (R01)

This Funding Opportunity Announcement (FOA) encourages research projects that focus on innovative research in the isolation and characterization of exosomes and their cargo for discovery of predictive biomarkers for risk assessment, detection, diagnosis and prognosis of early cancer. This FOA will promote rigor and reproducibility research in both the isolation of exosomes as well as the computational analysis of the cargo carried in these vesicles.

Deadline: June 13, 2018 OR October 15, 2018

   

Stimulating Innovations in Behavioral Intervention Research for Cancer Prevention and Control (R21)

The purpose of this Funding Opportunity Announcement (FOA) is to provide support for the development of innovative interventions that improve cancer-related health behaviors across diverse racial/ethnic populations. Specifically, this FOA is intended to stimulate research aimed at 1) testing new theories and conceptual frameworks; 2) developing and evaluating novel strategies to improve cancer-related health behaviors; 3) investigating multi-level and multi-behavioral approaches; and 4) utilizing innovative research designs, methodologies, and technologies. The cancer-related health behaviors to be targeted are diet, obesity, physical activity and sedentary behavior, smoking, sleep and circadian dysfunction, alcohol use, and/or adherence to cancer-related medical regimens. Research can involve any aspect of the cancer continuum and any phase of the translational spectrum.

Deadline: June 16, 2018 OR October 16, 2018

  

The Interplay of Cell Death Pathways in Cancer Cell Survival and Resistance to Therapy (R21)

The purpose of this funding opportunity announcement (FOA) is to stimulate research in the interplay between cell death pathways in nave and drug resistant cancers. Regulated cell death, especially apoptosis and necroptosis, are natural barriers that restrict malignant cells from surviving and disseminating. Evasion of cell death mechanisms is one of the hallmarks of cancer contributing to tumor progression, metastases and resistance to therapy. Recent studies show that the machinery to activate different forms of cell death coexists in cells but the crosstalk of cell death pathways in cancer has not been systematically studied. Research into the intersection of cell death programs will allow for better defining markers of cell death pathway at the molecular level and offers the possibility that the specific mediators of cell survival may be inhibited and/or the mediators of cell death enhanced, driving nave and drug resistant cancer cells toward effective cell death.

Deadline: October 16, 2018, February 16, 2019

   

Genome Sequencing Center for the Gabriella Miller Kids First Pediatric Research Program (U24 Clinical Trial Not Allowed)

The purpose of this Funding Opportunity Announcement (FOA) is to establish one or two centers that can rapidly generate high quality whole genome sequence and variant data from a large number of human specimens representing two types of pediatric conditions - childhood cancers and structural birth defects. All sequence data generated under this FOA will be re-processed and harmonized by the Gabriella Miller Kids First Pediatric Data Resource Center (Kids First DRC), which is also charged with building a public-facing, web-based portal that will allow researchers to search, access, aggregate, analyze, and share annotated genomic sequence, variant, and phenotypic datasets. Together these resources will promote comprehensive and cross-cutting research and collaboration within the pediatric research community.

Deadline: October 31, 2018

 

NCI Outstanding Investigator Award (R35 Clinical Trial Not Allowed)

This Funding Opportunity Announcement (FOA) invites grant applications for the Outstanding Investigator Award (R35) in any area of cancer research.

The objective of the National Cancer Institute (NCI) Outstanding Investigator Award (OIA) is to provide long-term support to accomplished investigators with outstanding records of cancer research productivity who propose to conduct exceptional research. The OIA is intended to allow investigators the opportunity to take greater risks, be more adventurous in their lines of inquiry, or take the time to develop new techniques. The OIA would allow an Institution to submit applications nominating established Program Directors/Principal Investigators (PDs/PIs) for the NCI OIA.

It is expected that the OIA would provide extended funding stability and encourage investigators to embark on projects of unusual potential in cancer research. The research projects should break new ground or extend previous discoveries toward new directions or applications that may lead to a breakthrough that will advance biomedical, behavioral, or clinical cancer research.

Deadline: November 2, 2018

   

Modular R01s in Cancer Control and Population Sciences (R01 Clinical Trial Optional)

This funding opportunity announcement (FOA) encourages applications for research in cancer control and population sciences. The overarching goal is to provide support to promote research efforts on novel scientific ideas that have the potential to substantially advance cancer research in statistical and analytic methods, epidemiology, cancer survivorship, cancer-related behaviors and behavioral interventions, health care delivery, and implementation science.

Deadline: November 7, 2018, March 6, 2019

   

The Role of Epitranscriptomics in Development and Disease (R01 - Clinical Trial Not Allowed)

The purpose of this Funding Opportunity Announcement (FOA) is to encourage applications from the scientific community to support outstanding research in the area of epitranscriptomics, i.e., the chemical modifications of RNA. Evidence is accumulating that RNA modifications regulate the function of both coding and noncoding RNAs, suggesting that these modifications are involved in both development, and in health and disease. Yet the extent and types of these RNA modifications as well as their roles in particular biological processes remain either poorly understood or not known. The goal of the FOA is to promote research into the role of RNA chemical modifications in the initiation and progression of various developmental processes and disease states and conditions relevant to the scientific mission of the participating ICs.

Deadline: November 7, 2018

 

Basic Research in Cancer Health Disparities (R01 Clinical Trial Not Allowed)

This Funding Opportunity Announcement (FOA) encourages grant applications from investigators interested in conducting basic, mechanistic research into the biological/genetic causes of cancer health disparities. These research project grants (R01) will support innovative studies designed to investigate biological/genetic bases of cancer disparities, such as (1) mechanistic studies of biological factors associated with cancer disparities, including those related to basic research in cancer biology or cancer prevention strategies, (2) the development and testing of new methodologies and models, and (3) secondary data analyses. This FOA is also designed to aid and facilitate the growth of a nationwide cohort of scientists with a high level of basic research expertise in cancer health disparities research who can expand available resources and tools, such as biospecimens, patient derived models, and methods that are necessary to conduct basic research in cancer health disparities.

Deadline: June 19, 2018; November 19, 2018

   

Exploratory/Developmental Grants Program for Basic Research in Cancer Health Disparities (R21 Clinical Trial Not Allowed)

This Funding Opportunity Announcement (FOA) encourages grant applications from investigators interested in conducting basic research studies into the biological/genetic causes and mechanisms of cancer health disparities. These awards will support pilot and feasibility studies designed to investigate biological/genetic bases of cancer disparities, such as (1) mechanistic studies of biological factors associated with cancer disparities, (2) the development and testing of new methodologies and models, and (3) secondary data analyses. This FOA is also designed to aid and facilitate the growth of a nationwide cohort of scientists with a high level of basic research expertise in cancer health disparities research who can expand available resources and tools, such as biospecimens, patient derived models and methods that are necessary to conduct basic research in cancer health disparities. In addition, the FOA will further the development of scientific areas, providing support for early-stage exploratory projects that lead to future in-depth mechanistic studies (such as R01 projects) of the biology of cancer health disparities. 

Deadline: June 19, 2018; November 19, 2018

 

Oncology Co-Clinical Imaging Research Resources to Encourage Consensus on Quantitative Imaging Methods and Precision Medicine (U24 - Clinical Trial Optional)

The purpose of this Funding Opportunity Announcement (FOA) is to invite Cooperative Agreement applications to develop research resources that will encourage a consensus on how Quantitative Imaging (QI) methods are optimized to improve the quality of imaging results for co-clinical trials.

The scientific goals of this FOA are to: (a) perform the appropriate optimization of the pre-clinical quantitative imaging methods, (b) implement the optimized methods in the co-clinical trial, and finally (c) populate a web-accessible research resource with all the data, methods, workflow documentation, and results collected from the co-clinical investigations.

Co-clinical trials are defined in this FOA as investigations in patients and in parallel (or sequentially) in mouse or human-in-mouse models of cancer that mirror the genetics and biology of the patients' malignancies or pre-cancerous lesions. The co-clinical trial should include either (a) a therapeutic goal, such as the prediction, staging, and/or measurement of tumor response to therapies, or (b) a screening and early detection or a cancer risk stratification goal for lethal cancer versus non-lethal disease.

Applicants are encouraged to organize multi-disciplinary teams with experience in mouse models research, human investigations, imaging platforms, QI methods, decision support software and informatics to populate the research resource.

Deadline: Application due- November 19, 2018

  

Emerging Questions in Cancer Systems Biology (U01)

The National Cancer Institute (NCI) is sponsoring a new Cancer Systems Biology Consortium (CSBC) that includes U54 CSBC Research Centers (RFA-CA-15-014), a U24 CSBC Coordinating Center (RFA-CA-15-015) and, through this FOA, well-defined, discrete and circumscribed Research Projects addressing emerging problems in cancer. The CSBC initiative aims to address challenges in cancer research through the use of experimental biology or population science combined with in silico modeling, multi-dimensional data analysis, and systems engineering.

This Funding Opportunity Announcement (FOA) invites cooperative agreement applications for Research Projects that utilize systems biology approaches to address emerging questions in cancer initiation, progression, and treatment. CSBC Research Projects are expected to involve interdisciplinary teams of physical scientists (e.g., engineers, chemists, computer scientists, mathematicians, physicists, population scientists, statisticians, epidemiologists) and cancer researchers (e.g., cancer biologists, oncologists, pathologists and clinicians in relevant disciplines) who collaborate to advance our understanding of cancer biology and oncology. CSBC Research Projects proposed in response to this FOA must demonstrate explicit integration of experimental biology and computational modeling to test and validate novel hypotheses in cancer research.

Clinical Trials Not Allowed for due dates on or after January 25, 2018: Only accepting applications that do not propose clinical trials

Deadline: November 23, 2018

 

Discovery of Biomarkers, Biomarker Signatures, and Endpoints for Pain (R61/R33 Clinical Trial Optional)

The overarching purpose of this Funding Opportunity Announcement (FOA) is to promote the discovery of strong candidate biomarkers and endpoints for pain that can be used to facilitate the development of non-opioid pain therapeutics from discovery through Phase II clinical trials. Specifically, the focus of this FOA is on the identification and initial biological, analytical and clinical validation of pain biomarkers, biomarker signatures, and/or endpoints. Although research supported by this FOA can include animal studies, it must also include preliminary human validation using carefully standardized human samples or human clinical studies. The goal of this initiative is to deliver candidate biomarkers, biomarker signatures, and/or endpoints that are ready for advanced clinical and analytical validation research.

Deadline: November 27, 2018, LOI 30 days prior

   

Comprehensive Partnerships to Advance Cancer Health Equity (CPACHE) (Collaborative U54 Clinical Trial Optional)

This funding opportunity seeks to support the Comprehensive Partnerships to Advance Cancer Health Equity (CPACHE) Program. The CPACHE Program develops and maintains comprehensive, long-term, and mutually beneficial partnerships between institutions serving underserved health disparity population and underrepresented students (ISUPSs) and NCI-designated Cancer Centers (CCs). The program aims to achieve a stronger national cancer program and address challenges in cancer and cancer disparities research, education and outreach, as well as their impact on underserved populations.

The institutions in each partnership are expected to work collaboratively to: 1) increase the cancer research and cancer research education capacity of the ISUPSs; 2) increase the number of students and investigators from underrepresented populations engaged in cancer research; 3) improve the effectiveness of CCs in developing and sustaining research programs focused on cancer health disparities and increase the number of investigators and students conducting cancer health disparities research; and 4) develop and implement cancer-related activities that benefit the surrounding underserved communities

Deadline: January 9, 2019

 

Short-term Mentored Career Enhancement Awards for Mid-Career Investigators to Integrate Basic Behavioral and Social Sciences (K18-No Independent Clinical Trials)

This Funding Opportunity Announcement (FOA) encourages applications for short-term mentored career development (K18) awards that improve synergies among researchers in basic and applied behavioral-social sciences, human subjects and model animals settings; and biomedical and behavioral-social sciences.

This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary study to a clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor. Applicants proposing a clinical trial or an ancillary study to an ongoing clinical trial as lead investigator, should apply to the companion FOA (FOA #).

Deadline:

  • March 6, 2019

The National Institutes of Health (NIH) hereby notify Program Directors/Principal Investigators (PD(s)/PI(s)) holding specific types of NIH research grants listed in the full Funding Opportunity Announcement (FOA) that funds may be available for administrative supplements to meet increased costs that are within the scope of the approved award, but were unforeseen when the new or renewal application or grant progress report for non-competing continuation support was submitted. Applications for administrative supplements are considered prior approval requests (as described in Section 8.1.2.11 of the NIH Grants Policy Statement) and will be routed directly to the Grants Management Officer of the parent award.

Deadline: Due dates vary by awarding IC

 

NCI Transition Career Development Award to Promote Diversity

The purpose of the NCI Transition Career Development Award to Promote Diversity is to assist postdoctoral fellows or individuals in equivalent positions to transition to positions of assistant professor or equivalent and initiate a successful biomedical career as an independent research scientist.

Deadline: Standard Dates Apply

Bioengineering Research Grants (BRG) (R01 Clinical Trial Optional)

The purpose of this funding opportunity announcement is to encourage collaborations between the life and physical sciences that: 1) apply a multidisciplinary bioengineering approach to the solution of a biomedical problem; and 2) integrate, optimize, validate, translate or otherwise accelerate the adoption of promising tools, methods and techniques for a specific research or clinical problem in basic, translational, or clinical science and practice. An application may propose design-directed, developmental, discovery-driven, or hypothesis-driven research and is appropriate for small teams applying an integrative approach to increase our understanding of and solve problems in biological, clinical or translational science.

Deadline: Standard Dates Apply

 

Cancer Research Education Grants Program - Curriculum or Methods Development (R25)

The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The over-arching goal of this NCI R25 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nation’s biomedical, behavioral and clinical research needs.

To accomplish the stated over-arching goal, this FOA will support creative educational activities with a primary focus on Curriculum or Methods Development. Applications are encouraged that propose innovative, state-of-the-art programs that address the cause, diagnosis, prevention, or treatment of cancer, rehabilitation from cancer, or the continuing care of cancer patients and the families of cancer patients.

Deadline: Standard Dates Apply

   

Cancer Research Education Grants Program - Courses for Skills Development (R25)

The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The over-arching goal of this NCI R25 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nation’s biomedical, behavioral and clinical research needs.

To accomplish the stated over-arching goal, this FOA will support creative educational activities with a primary focus on Courses for Skills Development. Applications are encouraged that propose innovative, state-of-the-art programs that address the cause, diagnosis, prevention, or treatment of cancer, rehabilitation from cancer, or the continuing care of cancer patients and the families of cancer patients.

Deadline: Standard Dates Apply

   

Cancer Research Education Grants Program - Research Experiences (R25)

The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The over-arching goal of this NCI R25 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nation’s biomedical, behavioral and clinical research needs.

To accomplish the stated over-arching goal, this FOA will support creative educational activities with a primary focus on Research Experiences. Applications are encouraged that propose innovative, state-of-the-art programs that address the cause, diagnosis, prevention, or treatment of cancer, rehabilitation from cancer, or the continuing care of cancer patients and the families of cancer patients.

Deadline: Standard Dates Apply

   

Developing the Therapeutic Potential of the Endocannabinoid System for Pain Treatment (R01 Clinical Trial Optional)

The purpose of this Funding Opportunity Announcement (FOA) is to support projects that will elucidate the therapeutic potential of the cannabinoids and endocannabinoid system in the development of mechanism-based therapies for pain.

Deadline: Standard Dates Apply

   

Education and Health: New Frontiers

The goal of this funding opportunity announcement is to support research that will further elucidate the pathways involved in the relationship between education and health outcomes and in doing so to carefully identify the specific aspects and qualities of education that are responsible for this relationship and what the mediating factors are that affect the nature of the causal relationship.

Deadline: Standard Dates Apply

 

End-of-Life and Palliative Needs of Adolescents and Young Adults (AYA) with Serious Illnesses

The purpose of this funding opportunity announcement (FOA) is to foster research on the unique perspectives, needs, wishes, and decision-making processes of adolescents and young adults (AYA; defined by the World Health Organization and the Centers for Disease Control and Prevention as youth between 12 – 24 years of age) with serious, advanced illnesses; and research focused on specific end-of-life/palliative care (EOLPC) models that support the physical, psychological, spiritual, and social needs of AYA with serious illness, their families and caregivers.

Deadline: Standard Dates Apply

Integration of Imaging and Fluid-Based Tumor Monitoring in Cancer Therapy (R01 Clinical Trial Optional)

Through this funding opportunity announcement (FOA), the National Cancer Institute (NCI) seeks research project (R01) grant applications describing projects that integrate imaging and fluid-based tumor monitoring (liquid biopsy) assays during cancer therapy in patients to determine the optimal use of those modalities in the characterization of therapy response and/or emergence of resistance.

Deadline: Standard Dates Apply

   

Integrative Research on Polysubstance Abuse and Addiction (R21/R33 Clinical Trial Optional)

This Funding Opportunity Announcement (FOA) is supported by Collaborative Research on Addiction (CRAN) at the National Institutes of Health (NIH), a trans-NIH partnership composed of the National Institute on Alcohol Abuse and Alcoholism (NIAAA), the National Institute on Drug Abuse (NIDA), and the National Cancer Institute (NCI). The intent of this FOA is two-fold: (1) characterize how the neurobiological alterations, associated behaviors, and public health consequences arising from polysubstance use differ from, or are similar to, those observed in single drug use; (2) promote integrative polysubstance research along a translational pipeline, consisting of basic science research in animals, human-based laboratory investigations, and epidemiological studies. These dual objectives will be accomplished with a Phased Innovation (R21/R33) mechanism, where polysubstance research can occur in any of these translational stages during the R21 phase and these findings will be rapidly back- or forward-integrated into another stage during the R33 phase, allowing for bi-directional research exchange.

Deadline: Standard Dates Apply

   

Linking the Provider Recommendation to Adolescent HPV Vaccine Uptake

This Funding Opportunity Announcement (FOA) encourages research on how the healthcare delivery system enhances or inhibits the effectiveness of a provider's recommendation of the adolescent human papillomavirus (HPV) vaccine. Characteristics of the provider, parent/patient, and clinical setting, can all affect whether a provider makes a recommendation, and whether that recommendation results in uptake of the HPV vaccine. This research requires expertise in cancer prevention, adult and childhood behavior, immunization promotion, and healthcare delivery.

Deadline: Standard Dates Apply

Mechanisms, Models, Measurement, & Management in Pain Research (R21 Clinical Trial Optional)

The purpose of this Funding Opportunity Announcement (FOA) is to inform the scientific community of the pain research interests of the various Institutes and Centers (ICs) at the National Institutes of Health (NIH) and to stimulate and foster a wide range of basic, clinical, and translational studies on pain as they relate to the missions of these ICs. New advances are needed in every area of pain research, from the micro perspective of molecular sciences to the macro perspective of behavioral and social sciences. Although great strides have been made in some areas, such as the identification of neural pathways of pain, the experience of pain and the challenge of treatment have remained uniquely individual and unsolved. Furthermore, our understanding of how and why individuals transition to a chronic pain state after an acute injury is limited. Research to address these issues conducted by interdisciplinary and multidisciplinary research teams is strongly encouraged, as is research from underrepresented, minority, disabled, or women investigators.

Deadline: Standard Dates Apply

   

Mentored Clinical Scientist Research Career Development Award

The primary purpose of the NIH Mentored Clinical Scientist Research Career Development Awards (K08) program is to prepare qualified individuals for careers that have a significant impact on the health-related research needs of the Nation. This program represents the continuation of a long-standing NIH program that provides support and "protected time" to individuals with a clinical doctoral degree for an intensive, supervised research career development experience in the fields of biomedical and behavioral research, including translational research.

Deadline: Standard Dates Apply

Methodology and Measurement in the Behavioral and Social Sciences

The purpose of this Funding Opportunity Announcement (FOA) is to invite qualified researchers to submit grant applications aimed at improving and developing methodology in the behavioral and social sciences through innovations in research design, measurement, data collection and data analysis techniques.

The participating NIH Institutes and Centers (ICs) encourage research that will improve the quality and scientific power of behavioral and social science data relevant to the IC missions. Applicants are strongly encouraged to contact the Scientific/Research Contact (see Section VII, Agency Contacts) of the IC that most closely matches their research focus to determine IC interest in the proposed research topic.

Deadline: Standard Dates Apply

NCI Mentored Research Scientist Development Award to Promote Diversity (K01)

The purpose of the NCI Mentored Research Scientist Development Award (K01) is to enhance the diversity of the pool of the NCI-funded cancer research workforce by supporting eligible individuals from groups that have been shown to be nationally underrepresented in the biomedical, behavioral, social and clinical sciences. This FOA provides salary and research support for a sustained period of "protected time" for intensive research career development under the guidance of an experienced mentor.

The Diversity Training Branch (DTB) of the Center to Reduce Cancer Health Disparities (CRCHD), at the National Cancer Institute (NCI), invites career development award applications (K01) from individuals from backgrounds that have been shown to be nationally underrepresented in health-related sciences.

This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary study to an existing trial, as part of their research and career development. Applicants not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to the companion FOA.

Deadline: Standard Dates Apply

   

NCI Small Grants Program for Cancer Research (NCI Omnibus R03 Clinical Trial Optional)

This funding opportunity announcement (FOA) supports small research projects on cancer that can be carried out in a short period of time with limited resources. The R03 grant mechanism supports different types of projects including pilot and feasibility studies; secondary analysis of existing data; small, self-contained research projects; development of research methodology; and development of new research technology.  

Deadline: Standard Dates Apply

   

Population Health Interventions: Integrating Individual and Group Level Evidence

To improve health and reduce the burden of disease, scientific research needs to be implemented at the population level in addition to the biological and clinical levels. The purpose of this funding opportunity announcement (FOA) is to support multilevel, transdisciplinary population health interventions that target underlying social, economic, and environmental conditions in an effort to improve health outcomes.

Deadline: Standard Dates Apply

Research Supplements to Promote Diversity in Health-Related Research (Admin Supp)

The National Institutes of Health (NIH) hereby notify Program Director(s)/Principal Investigator(s) (PD(s)/PI(s)) holding specific types of research grants (activity codes listed above) that funds are available for administrative supplements to improve the diversity of the research workforce by recruiting and supporting students, postdoctorates, and eligible investigators from groups that have been shown to be underrepresented in health-related research. This supplement opportunity is also available to PD(s)/PI(s) of research grants who are or become disabled and need additional support to accommodate their disability in order to continue to work on the research project. Administrative supplements must support work within the scope of the original project.

Deadline: Due dates vary by awarding IC

   

Ruth L. Kirschstein National Research Service Award (NRSA) Institutional Research Training Grant (Parent T32)

The National Institutes of Health (NIH) will award Ruth L. Kirschstein National Research Service Award (NRSA) Institutional Research Training Grants (T32) to eligible, domestic institutions to enhance predoctoral and postdoctoral research training, including short-term research training, and help ensure that a diverse and highly trained workforce is available to meet the needs of the Nation’s biomedical, behavioral, and clinical research agenda. Research training programs will incorporate didactic, research, and career development elements to prepare individuals for careers that will have a significant impact on the health-related research needs of the Nation. Programs proposing only short-term research training should not apply to this announcement, but rather to the Kirschstein-NRSA Short-Term Institutional Research Training Grant Program (T35) exclusively reserved for predoctoral, short-term research training.

Deadline: Standard Dates Apply

   

Stimulating Innovations in Behavioral Intervention Research for Cancer Prevention and Control (R21 Clinical Trial Optional)

The purpose of this Funding Opportunity Announcement (FOA) is to provide support for the development of innovative interventions that improve cancer-related health behaviors across diverse racial/ethnic populations. Specifically, this FOA is intended to stimulate research aimed at 1) testing new theories and conceptual frameworks; 2) developing and evaluating novel strategies to improve cancer-related health behaviors; 3) investigating multi-level and multi-behavioral approaches; and 4) utilizing innovative research designs, methodologies, and technologies. The cancer-related health behaviors to be targeted are diet, obesity, physical activity and sedentary behavior, smoking, sleep and circadian dysfunction, alcohol use, and/or adherence to cancer-related medical regimens. Research can involve any aspect of the cancer continuum and any phase of the translational spectrum.

Deadline: Standard Dates Apply

   

Target Assessment, Engagement and Data Replicability to Improve Substance Use Disorders Treatment Outcomes (R21/R33 Clinical Trial Optional)

This Funding Opportunity Announcement (FOA) is part of an NIH initiative known as Collaborative Research on Addiction at NIH (CRAN). Areas supported by this FOA include research to generate and conduct preliminary tests of targeted addiction treatment to address multiple substances, which may include alcohol, tobacco and other drug use (ATOD).

This FOA encourages applications that focus on early-stage, treatment generation and pilot clinical trials that are consistent with an experimental therapeutic approach. This approach requires the identification of a theory-derived target based on putative mechanisms of alcohol, tobacco and other drug use, and clear hypotheses about how a treatment directed at changing the target can lead to clinical benefits.

Studies of novel treatments include, but are not limited to behavioral, pharmacological, physiological, learning- and device-based treatment approaches. This FOA provides support for up to two years (Phase I; R21) for protocol development, target identification and studies to confirm target engagement (i.e., link targets with tangible outcomes); followed by up to 3 years of support (Phase II; R33) for replication studies of addiction treatment across 2 or more settings. Specifically, this latter phase will focus on clinical trials that apply the target in a treatment setting (development, refinement, and/or adaptation) to evaluate the feasibility of conducting a larger trial.

Deadline: Standard Dates Apply

   

The Health of Sexual and Gender Minority (SGM) Populations

The National Institutes of Health (NIH) is committed to supporting research that will increase scientific understanding of the health status of diverse population groups and thereby improve the effectiveness of health interventions and services for individuals within those groups. Priority is placed on understudied populations with distinctive health risk profiles. This funding opportunity announcement (FOA) focuses on sexual and gender minority (SGM) populations, including lesbian, gay, bisexual, transgender, and intersex populations. Basic, social, behavioral, clinical, and services research relevant to the missions of the sponsoring Institutes and Centers may be proposed.

Deadline: Standard Dates Apply

The NCI Transition Career Development Award

This Funding Opportunity Announcement (FOA) supports an NCI program that facilitates the transition of investigators in mentored, non-independent cancer research positions to independent faculty cancer research positions. This goal is achieved by providing protected time through salary and research support for the initial 3 years of the first independent tenure-track faculty position, or its equivalent, beginning at the time when the candidate starts a tenure-track faculty position.

Time-Sensitive Obesity Policy and Program Evaluation (R01)

This Funding Opportunity Announcement (FOA) establishes an accelerated review/award process to support time-sensitive research to evaluate a new policy or program that is likely to influence obesity related behaviors (e.g., dietary intake, physical activity, or sedentary behavior) and/or weight outcomes in an effort to prevent or reduce obesity. This FOA is intended to support research where opportunities for empirical study are, by their very nature, only available through expedited review and funding.

All applications to this FOA must demonstrate that the evaluation of an obesity related policy and /or program offers an uncommon and scientifically compelling research opportunity that will only be available if the research is initiated with minimum delay. For these reasons, applications in response to this time-sensitive FOA are not eligible for resubmission. It is intended that eligible applications selected for funding will be awarded within four months of the application due date. However, administrative requirements and other unforeseen circumstances may delay issuance dates beyond that timeline.

Applications due on a continuous basis (once per month)

 

Department of Defense (DOD)

DoD Prostate Cancer, Physician Research Award

Applications to the Fiscal Year 2018 (FY18) Prostate Cancer Research Program (PCRP) are being solicited for the Defense Health Agency (DHA) J9, Research and Development Directorate, by the U.S. Army Medical Research Acquisition Activity (USAMRAA) using delegated authority provided by United States Code, Title 10, Section 2358 (10 USC 2358).

The mission of the FY18 PCRP is to fund research that will lead to the elimination of death from prostate cancer and enhance the well-being of Service members, Veterans, and all men experiencing the impact of the disease. Within this context, the PCRP is interested in supporting research that addresses specific gaps in prostate cancer research and clinical care. Therefore, applications are required to address one or more of the following FY18 PCRP Overarching Challenges:

  • Develop treatments that improve outcomes for men with lethal prostate cancer
  • Reduce lethal prostate cancer in African Americans, Veterans, and other high-risk populations
  • Define the biology of lethal prostate cancer to reduce death
  • Improve the quality of life for survivors of prostate cancer

The Physician Research Award supports a mentored research experience to prepare physicians with clinical duties and/or responsibilities for productive careers in prostate cancer research. The mentored physician is considered the Principal Investigator (PI) of the application. This award emphasizes equally the quality of the proposed research project and the career development of the PI, which should prepare physicians for careers in basic, population science, translational, or clinical prostate cancer research.

Deadlines:

  • Preapplication August 16, 2018
  • Application September 6, 2018

DoD Lung Cancer

Applications to the Fiscal Year 2018 (FY18) Lung Cancer Research Program (LCRP) are being solicited for the Defense Health Agency (DHA) J9, Research and Development Directorate, by the U.S. Army Medical Research Acquisition Activity (USAMRAA) using delegated authority provided by United States Code, Title 10, Section 2358 (10 USC 2358). The goal of the FY18 LCRP is to eradicate deaths and suffering from lung cancer to better the health and welfare of the military Service members, Veterans, and the American public. As such, the LCRP will support and integrate research from multiple disciplines for risk assessment, prevention, early detection, diagnosis, and treatment for the control and cure of lung cancer.

Deadline: September 26, 2018

DoD Prostate Cancer, Idea Development Award

Applications to the Fiscal Year 2018 (FY18) Prostate Cancer Research Program (PCRP) are being solicited for the Defense Health Agency (DHA) J9, Research and Development Directorate, by the U.S. Army Medical Research Acquisition Activity (USAMRAA) using delegated authority provided by United States Code, Title 10, Section 2358 (10 USC 2358).

The mission of the FY18 PCRP is to fund research that will lead to the elimination of death from prostate cancer and enhance the well-being of Service members, Veterans, and all men experiencing the impact of the disease. Within this context, the PCRP is interested in supporting research that addresses specific gaps in prostate cancer research and clinical care. Therefore, applications are required to address one or more of the following FY18 PCRP Overarching Challenges:

  • Develop treatments that improve outcomes for men with lethal prostate cancer
  • Reduce lethal prostate cancer in African Americans, Veterans, and other high-risk populations
  • Define the biology of lethal prostate cancer to reduce death
  • Improve the quality of life for survivors of prostate cancer

The Idea Development Award is intended to support new ideas that represent innovative approaches to prostate cancer research and have the potential to make an important contribution to the PCRP mission. The key components of this award mechanism are:

Innovation: Research deemed innovative may represent a new paradigm, challenge current paradigms, look at existing problems from new perspectives, leverage unique study populations, or exhibit other highly creative qualities. Research that is an incremental advance upon published data is not considered innovative. Multidisciplinary projects are especially encouraged.

Impact: Applications are required to address and provide a solution to one or more of the PCRP Overarching Challenges. The potential impact of the research, both short-term and long-term, in addressing the PCRP Overarching Challenge(s) should be clearly described. High-impact research will, if successful, significantly advance prostate cancer research and/or patient care.

Preliminary Data: Due to this award's emphasis on innovation, the presentation of preliminary data relevant to prostate cancer and the proposed project is encouraged, but not required. Any unpublished, preliminary data provided should originate from the laboratory of the Principal Investigator (PI) or a member(s) of the research team. Regardless of whether preliminary data is included or not, applications should be based on a sound scientific rationale that is established through logical reasoning and/or critical review and analysis of the literature.

Deadlines:

  • Preapplication July 6, 2018
  • Application September 27, 2018

DoD Prostate Cancer, Impact Award

Applications to the Fiscal Year 2018 (FY18) Prostate Cancer Research Program (PCRP) are being solicited for the Defense Health Agency (DHA) J9, Research and Development Directorate, by the U.S. Army Medical Research Acquisition Activity (USAMRAA) using delegated authority provided by United States Code, Title 10, Section 2358 (10 USC 2358).

The mission of the FY18 PCRP is to fund research that will lead to the elimination of death from prostate cancer and enhance the well-being of Service members, Veterans, and all men experiencing the impact of the disease. Within this context, the PCRP is interested in supporting research that addresses specific gaps in prostate cancer research and clinical care. Therefore, applications are required to address one or more of the following FY18 PCRP Overarching Challenges:

  • Develop treatments that improve outcomes for men with lethal prostate cancer
  • Reduce lethal prostate cancer in African Americans, Veterans, and other high-risk populations
  • Define the biology of lethal prostate cancer to reduce death
  • Improve the quality of life for survivors of prostate cancer

The Impact Award supports research projects that have the strong potential to make a major impact on scientific and clinical prostate cancer issues, and ultimately make major advances toward eliminating death from prostate cancer and enhancing the well-being of Service members, Veterans, and all men experiencing the impact of the disease.

Deadlines

  • Preapplication July 19, 2018
  • Application October 18, 2018

Foundations & Organizations

Graduate Training in Disparities Research (GTDR) | Komen for the Cure, Susan G.

Graduate Training in Disparities Research (GTDR) Grants are intended to establish and/or to sustain a training program for graduate students who are seeking careers dedicated to understanding and eliminating disparities in breast cancer outcomes across population groups.

By providing funding to outstanding training programs, Komen seeks to ensure that a diverse pool of highly trained scientists will emerge as the next generation of leaders in the field of breast cancer research focused on disparities in breast cancer outcomes.

The research training program should be designed to meet the following goals:

  • Attract graduate students, specifically those from populations affected by disparities in breast cancer outcomes, into research careers.
     
  • Empower these students with the skills and knowledge necessary to effectively explore the causes of differential breast cancer outcomes and develop interventions to reduce and eliminate such disparities.

Deadline TBA

 

Distinguished Scholars | Lustgarten Foundation

The Distinguished Scholars program supports world-class scientists, who are at the top in their field, and are at the forefront of today's most exciting breakthroughs in pancreatic cancer research. Selected by The Lustgarten Foundation's Scientific Advisory Board (SAB), each grantee will receive $5 million in funding over the next five years, enabling these scientists to purse high-risk high-reward science, dedicate more of their time and focus to pancreatic cancer research, and accelerate a path to a cure.

The Distinguished Scholar Award is given on a discretionary basis and is not part of the annual grant program.

 

Komen Southeast Wisconsin's Small Grant Program

Any non-profit organization in the Komen Southeast Wisconsin service area can apply for up to $5,000 for a small pilot or capacity-building breast health program grant. These grants are for organizations interested in beginning a new program or testing new ideas that will increase the innovative capacity and effectiveness of breast health programs that serve low income and uninsured women.

Small Grants are available in two categories:

  1. Education/Outreach Grants will support the development of breast cancer programs or projects.
     
  2. Capacity Building/Technical Assistance Grants will provide funding to increase the efficiency and effectiveness of an organization's ability to provide services by redesigning processes, implementing new practices, or developing collaborations or partnerships.

Applications due on a continuous basis throughout funding cycle

   

Pediatric Low Grade Astrocytomas Foundation (PLGA)

The number one priority of A Kids' Brain Tumor Cure Foundation is to act as a catalyst for researchers world-wide to turn their attention to the area of pediatric low grade glioma brain tumor research and to award research grants for the most promising programs and studies. The hope is that this research will lead to a better understanding of the causes of PLGA as well as the discovery of more effective treatments and a cure for the most common forms of children's brain tumors.

Proposals related to basic and translational* projects that can advance understanding of the underlying biology of the development and treatment of PLGA tumors will be considered.

*NIH definition of translational research: the process of applying ideas, insights, and discoveries generated through basic scientific inquiry to the treatment or prevention of human disease.

Applications continuous

   

SWOG Trial Support (STrS) – The Hope Foundation

SWOG's mission is to improve the practice of cancer medicine in preventing, detecting, and treating cancer, and to enhance the quality of life for cancer survivors, primarily through design and conduct of clinical trials. SWOG is a National Cancer Institute-supported network of more than 5,000 cancer researchers at more than 650 institutions in the U.S., Canada, and beyond. Additional educational and cancer research support is provided by SWOG's non-profit, philanthropic partner, The Hope Foundation.

STrS is a peer-reviewed program administered by The Hope Foundation in conjunction with SWOG. STrS is designed to support trial components that need supplemental funding during patient enrollment in a SWOG study. Qualifying components may include things that are outside of the SWOG-supported norm, such as atypical requests for tissue and/or data, or provision of materials to trial sites.

Applications continuous

 

Institutional

Other

AACR Scientific Achievement Awards - AACR-American Cancer Society Award for Research Excellence in Cancer Epidemiology and Prevention

The AACR and the American Cancer Society established this award in 1992 to honor outstanding research accomplishments in the fields of cancer epidemiology, biomarkers, and prevention

Deadline: August 8, 2018

   

AACR Scientific Achievement Awards - AACR Princess Takamatsu Memorial Lectureship

The AACR Princess Takamatsu Memorial Lectureship was established and first presented in 2007 in honor of the late Princess Takamatsu of Japan. During her extraordinary life, Her Imperial Highness Princess Takamatsu expended tremendous efforts toward the public and humanitarian cause of the eradication of cancer. She is regarded as an honored and respected figure in Japan, the United States, and within the international cancer research community as a whole.

This lectureship will recognize an individual scientist whose novel and significant work has had or may have a far-reaching impact on the detection, diagnosis, treatment, or prevention of cancer, and who embodies the dedication of the Princess to multinational collaborations.

Deadline: August 8, 2018

   

Kidney Cancer Research Program Concept Award

The FY18 KCRP Concept Award supports highly innovative, untested, potentially groundbreaking novel concepts in kidney cancer. The Concept Award is not intended to support an incremental progression of an already established research project but, instead, allows Principal Investigators (PIs) the opportunity to pursue serendipitous observations. Preliminary data are not allowed. This award mechanism supports high-risk studies that have the potential to reveal entirely new avenues for investigation. Applications must describe how the new idea will enhance the existing knowledge of kidney cancer or develop an innovative and novel course of investigation. Research completed through a Concept Award may generate sufficient preliminary data to enable the PI to prepare an application for future research.

Deadline: August 8, 2018

 

This grant is focused on addressing barriers to germline testing in hereditary Ovarian Cancer. The Foundation gratefully acknowledges Myriad Genetics for the support of this grant. This is the first year this research grant is being offered.

Deadline: August 27, 2018

 

Ovarian Cancer Research Grant in Honor of Liza D. Chance

The Foundation gratefully acknowledges Pippa Calland, and the friends and family of Liza D. Chance for the support of this grant. This is the first year this research grant is being offered.

Deadline: August 27, 2018

   

UICC's mission is to unite the cancer community, to reduce the global cancer burden, to promote greater equity, and to integrate cancer control into the world health and development agenda.

The Yamagiwa-Yoshida International Memorial (YY) Study Grant programme is an important part of UICC's International Fellowship portfolio and aims specifically at supporting established cancer investigators from any country to:

  • initiate, set up or pursue bilateral cancer research projects with collaborating investigators abroad
  • exchange complementary skills and materials
  • receive training in advanced experimental cancer research methods and techniques

Deadline: September 15, 2018

   

Prostate Cancer Research Program Health Disparity Research Award

The Health Disparity Research Award supports promising research ideas that have high potential to make a significant impact in eliminating disparities in prostate cancer incidence, morbidity, mortality, and survivorship. The PCRP is interested in research that addresses all different aspects that contribute to health disparity in prostate cancer, including, but not limited to, social, cultural, and/or biological contributors. Proposed research ideas should be innovative, but primary emphasis will be placed on the potential impact of the proposed work.

Deadline: Pre-Application September 20, 2018. Application October 15, 2018

   

Career Development Award (CDA)

The CDA provides research funding to clinical investigators, who have received their initial faculty appointment, as they work to establish an independent clinical cancer research program. This research must have a patient-oriented focus, including a clinical research study and/or translational research involving human subjects. Proposals with a predominant focus on in vitro or animal studies (even if clinically relevant) are not allowed.

The Foundation has funding in 2018 for breast cancer but also encourages applications in all other areas.

Deadline: September 21, 2018

 

Kidney Cancer Research Program Idea Development Award

The FY18 KCRP Idea Development Award is intended to support innovative ideas and high-impact approaches based on scientifically sound evidence to move toward the KCRP vision of eliminating kidney cancer. The research project should include a well-formulated, testable hypothesis based on strong scientific rationale and a well-developed and articulated research approach relevant to active duty Service members, Veterans, other military beneficiaries, and the American public.

Deadline: September 26, 2018

   

Kidney Cancer Research Program Physician Research Award

The Physician Research Award supports a mentored research experience to prepare physician scientists for productive careers in kidney cancer research. The mentored physician is considered the Principal Investigator (PI) of the application. This award emphasizes equally the quality of the proposed research project and the career development of the PI, which should prepare physicians for careers in basic, population science, translational, or clinical kidney cancer research.

Deadline: September 26, 2018

   

Kidney Cancer Research Program Translational Research Partnership Award

The FY18 KCRP Translational Research Partnership Award mechanism supports partnerships between clinicians and research scientists that will accelerate the movement of promising ideas in kidney cancer toward clinical applications. This award supports the development of translational research collaborations between two independent, faculty-level (or equivalent) investigators to address a central problem or question in kidney cancer in a manner that would be less readily achievable through separate efforts. One partner in the collaboration must be a research scientist and the other must be a clinician. It should be clear that both have had equal intellectual input in the design of the research project. Multi-institutional partnerships are encouraged. At least one member of the partnership must have experience either in kidney cancer research or kidney cancer patient care. Inclusion of experts from outside the kidney cancer field is encouraged. A proposed project in which the clinical partner merely supplies tissue samples or access to patients will not meet the intent of this award mechanism.

Deadline: September 26, 2018

   

Kidney Cancer Research Program Technology Development Award

The KCRP Technology Development Award is a product-driven award mechanism intended to advance the development of technologies to aid kidney cancer clinical and patient outcomes, including prevention, detection, diagnosis, treatment, or quality of life. Applicants with limited kidney cancer experience are strongly encouraged to collaborate with those having substantial expertise in kidney cancer research and/or kidney cancer model systems. Applications must describe how the technology will enhance the existing knowledge of kidney cancer.

The product(s) to be developed may be a tangible item such as a pharmacologic agent (drugs or biologics) or device. The Principal Investigator (PI) must provide a transition plan (including potential funding and resources) showing how the product will progress to the next level of development (e.g., clinical trials, delivery to the military or civilian market) after the completion of the KCRP award.

Deadline: September 26, 2018

   

Peer Reviewed Cancer Research Program - Horizon Award

To be considered for funding, applications for the FY18 PRCRP Horizon Award must address at least one of the FY18 PRCRP Topic Areas as directed by Congress. Research applications in the areas of breast, prostate, lung (excluding mesothelioma), kidney, or ovarian cancer will not be accepted. The FY18 PRCRP Topic Areas are listed below:

  • Adrenal cancer
  • Melanoma and other skin cancers
  • Bladder cancer
  • Mesothelioma
  • Blood cancers
  • Myeloma
  • Brain cancer
  • Neuroblastoma
  • Colorectal cancer
  • Pancreatic cancer
  • Immunotherapy
  • Pediatric brain tumors
  • Listeria-based regimens for cancer
  • Stomach cancer
  • Liver cancer
  • Cancer in children, adolescents, and young adults
  • Lymphoma

Deadline: September 26, 2018

   

DoD Prostate Cancer, Idea Development Award

Applications to the Fiscal Year 2018 (FY18) Prostate Cancer Research Program (PCRP) are being solicited for the Defense Health Agency (DHA) J9, Research and Development Directorate, by the U.S. Army Medical Research Acquisition Activity (USAMRAA) using delegated authority provided by United States Code, Title 10, Section 2358 (10 USC 2358).

The mission of the FY18 PCRP is to fund research that will lead to the elimination of death from prostate cancer and enhance the well-being of Service members, Veterans, and all men experiencing the impact of the disease. Within this context, the PCRP is interested in supporting research that addresses specific gaps in prostate cancer research and clinical care. Therefore, applications are required to address one or more of the following FY18 PCRP Overarching Challenges:

  • Develop treatments that improve outcomes for men with lethal prostate cancer
  • Reduce lethal prostate cancer in African Americans, Veterans, and other high-risk populations
  • Define the biology of lethal prostate cancer to reduce death
  • Improve the quality of life for survivors of prostate cancer

The Idea Development Award is intended to support new ideas that represent innovative approaches to prostate cancer research and have the potential to make an important contribution to the PCRP mission. The key components of this award mechanism are:

Innovation: Research deemed innovative may represent a new paradigm, challenge current paradigms, look at existing problems from new perspectives, leverage unique study populations, or exhibit other highly creative qualities. Research that is an incremental advance upon published data is not considered innovative. Multidisciplinary projects are especially encouraged.

Impact: Applications are required to address and provide a solution to one or more of the PCRP Overarching Challenges. The potential impact of the research, both short-term and long-term, in addressing the PCRP Overarching Challenge(s) should be clearly described. High-impact research will, if successful, significantly advance prostate cancer research and/or patient care.

Preliminary Data: Due to this award's emphasis on innovation, the presentation of preliminary data relevant to prostate cancer and the proposed project is encouraged, but not required. Any unpublished, preliminary data provided should originate from the laboratory of the Principal Investigator (PI) or a member(s) of the research team. Regardless of whether preliminary data is included or not, applications should be based on a sound scientific rationale that is established through logical reasoning and/or critical review and analysis of the literature.

Deadlines:

  • Preapplication July 6, 2018
  • Application September 27, 2018
   

Unique AML Predisposition Grant-RUNX1/Alex’s Lemonade Stand

The purpose of the grant is to fund research in strategies leading to the development of therapies to prevent the transition from pre-leukemia to leukemia for patients with FPD/AML. Projects should focus on leukemia caused by familial RUNX1 mutations rather than sporadic AML with somatic RUNX1 mutations.

The Program is viewed as a long-term endeavor of collaboration and data sharing. We are especially interested in innovative and cross-disciplinary approaches to developing effective therapies.

Deadline: LOI Due: July 2, 2018 Application Due: 10/1/2018

   

RFA: The Role of Health Policy and Health Insurance in Improving Access to and Performance of Cancer Prevention, Early Detection, and Treatment Services

Purpose: A call for research that evaluates the impact of the many changes now occurring in the healthcare system with a particular focus on cancer prevention, control, and treatment. Efforts focusing on improving access to care may also impact inequities that contribute to health disparities. New health public policy initiatives such as the new federal and state marketplaces that have expanded insurance coverage, as well as Medicaid expansion in some states, create natural experiments ripe for evaluation. Research to be funded by this RFA should focus on the changes in national, state, and/or local policy and the response to these changes by healthcare systems, insurers, payers, communities, practices, and patients.

The association is keenly interested in supporting rapid learning research to study the effects of health policy changes on patients, providers, and health systems. This includes but is not limited to:

  • Facilitators and barriers to care;
  • Unintended consequences;
  • Differential experiences and outcomes of patients seeking or receiving care;
  • Best practice models for quality care; and,
  • Economic Impact

Deadline: October 15, 2018

   

DoD Prostate Cancer, Impact Award

Applications to the Fiscal Year 2018 (FY18) Prostate Cancer Research Program (PCRP) are being solicited for the Defense Health Agency (DHA) J9, Research and Development Directorate, by the U.S. Army Medical Research Acquisition Activity (USAMRAA) using delegated authority provided by United States Code, Title 10, Section 2358 (10 USC 2358).

The mission of the FY18 PCRP is to fund research that will lead to the elimination of death from prostate cancer and enhance the well-being of Service members, Veterans, and all men experiencing the impact of the disease. Within this context, the PCRP is interested in supporting research that addresses specific gaps in prostate cancer research and clinical care. Therefore, applications are required to address one or more of the following FY18 PCRP Overarching Challenges:

  • Develop treatments that improve outcomes for men with lethal prostate cancer
  • Reduce lethal prostate cancer in African Americans, Veterans, and other high-risk populations
  • Define the biology of lethal prostate cancer to reduce death
  • Improve the quality of life for survivors of prostate cancer

The Impact Award supports research projects that have the strong potential to make a major impact on scientific and clinical prostate cancer issues, and ultimately make major advances toward eliminating death from prostate cancer and enhancing the well-being of Service members, Veterans, and all men experiencing the impact of the disease.

Deadlines

  • Preapplication July 19, 2018
  • Application October 18, 2018
 

Translational Research Program (TRP)

The Leukemia & Lymphoma Society, Inc. (LLS) is a national voluntary health agency dedicated to the conquest of hematologic malignancies and relevant premalignant conditions. LLS supports research, patient aid, community service programs, advocacy, and public and professional education. The formation of the Translational Research Program (TRP) was to foster collaboration between basic and clinical scientists with the intent of enhancing the transfer of basic research findings to clinical usefulness.

Deadline: October 31, 2018

   

Collaborative Research Development Grant

This grant provides funds for large ovarian cancer research projects that involve several investigators within one institution or collaborations between groups in multiple institutions.

Deadline: To be Announced

   

Liz Tilberis Early Career Award

The Liz Tilberis Early Career Award is for junior faculty with a strong commitment to an investigative career in ovarian cancer research.

Deadline: To be Announced

 

Adenoid Cystic Carcinoma Research Foundation

Adenoid Cystic Carcinoma (ACC) is a rare malignancy of secretory glands, typically originating in the salivary glands though it does appear in other primary sites, including the palate, nasopharynx, tongue base, larynx, trachea, lacrimal gland, breast and vulva. There are approximately 1,200 new cases of ACC diagnosed each year in the United States, about 60% of which involve women. This cancer has a slow, and sometimes relentless, progression characterized by frequent recurrences and metastases to sites such as the lungs, liver and bones.

Deadline continuous

   

Boehringer Ingelheim Pharma GmbH & Co. KG | Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI)

Medical Educational Grants are independent educational activities that utilize effective educational methods to address unmet medical needs that leads to improved patient outcomes. A Boehringer Ingelheim Pharmaceuticals, Inc. medical educational grant is designed to provide support for accredited educational programs for health care providers and non-accredited educational programs directed toward the patient and the local health care community.

The Medical Education Grants Department consists of education professionals who facilitate lifelong learning for clinicians and patients through support of independent education. BIPI's Medical Education and Research Grants department is committed to supporting innovative, high quality, independent medical education and research for healthcare professionals and patients that resolves unmet medical needs, fosters clinical excellence, and measurably improves health outcomes in areas of strategic focus to BIPI.

The sponsor considers funding of activities in many therapeutic areas including:

  • Therapeutic Areas Cardiovascular Disease – Stroke Prevention in Atrial Fibrillation
  • Cardiovascular Disease – Venous Thromboembolism (VTE)
  • Immunology – General Immunology
  • Oncology – Acute Myeloid Leukemia (AML)
  • Oncology – Lung Cancer
  • Respiratory Disease – Chronic Obstructive Pulmonary Disease (COPD)
  • Respiratory Disease – Interstitial Lung Disease (ILD)

Funding may be limited or exhausted in some therapeutic areas. BIPI will review and consider support of those requests in the areas above. To that end, educational objectives have been identified that are derived from evidence based science and are intended to close gaps in research, knowledge, or behaviors that represent barriers in care and patient outcomes.

Deadline continuous

   

UICC Technical Fellowships (UICC-TF) [previously Global Education and Training Initiative (GETI): International Cancer Technology Transfer Fellowships (ICRETT)]

The aim of the UICC ICRETT fellowships is to facilitate rapid international transfer of cancer research and clinical technology, exchange knowledge and enhance skills in basic, clinical, behavioural and epidemiological areas of cancer research cancer control and prevention and to acquire appropriate clinical management, diagnostic and therapeutic expertise for effective application and use in the home organization upon return.

  • Research plan
    • Cancer prevention and control (including tobacco control)
    • Basic, applied and clinical cancer research Epidemiology,
    • Cancer registration, public education and behavioral sciences
  • Clinical training
    • Surgery, radio and chemotherapy, medical oncology, multidisciplinary cancer care
    • Clinical trials
    • Detection and diagnosis Prevention-oriented projects are especially encouraged

Deadline Continuous

 

Sanofi-Aventis U.S. Inc. Education Grants

Sanofi US is committed to funding high quality educational activities and materials in the therapeutic areas of interest to the company that have the potential to improve patient care and health outcomes.

The purpose of an educational grant is to support an activity that encourages an educational interchange with respect to available scientific and medical information. Educational activities may or may not be accredited.

Educational Grants fund educational activities and materials designed to improve the knowledge, competence (skill) and/or performance of healthcare professionals, patients, and/or consumers for improved patient care and outcomes.

Grants may be given for live educational activities, as well as educational publications and other types of enduring materials (e.g. interactive web, CD rom, audio tapes, etc.) provided that the activities or materials are advertised and open to a broad audience beyond members of the requesting institution. Fellowships or career development awards may be considered in limited circumstances.

Applicant must select one of the following Therapeutic Areas:

  • Cardiovascular
  • Diabetes
  • Genetic Diseases
  • Immunology
  • Multiple Sclerosis
  • Oncology
  • Orthopedics
  • Renal
  • Thyroid Cancer
  • Transplantation

Deadline continuous

 

Women's Cancer Research Grants

The FWC continues to seek additional funding to support expanded research priorities. Of special importance is increased funding for cervical, uterine, primary peritoneal, vaginal and vulvar cancer research. Additionally, the Foundation is seeking funding for a series of new types of research opportunities:

  • Post-Doctoral Fellowship grants: These grants are intended to attract and support promising young scientists and clinician/scientists to ensure the next generation of skilled researchers dedicated to gynecologic cancer research.
  • Career Development Awards: These grants are similar to the NIH CDA, K series awards, and are awarded to applicants who wish to further develop their careers in gynecologic cancer biomedical, behavioral or clinical research
  • Paired grants: Junior investigators would join with senior investigators for grants lasting two to three years.
  • Innovative grants: These grants would provide funding for creative and imaginative research projects that show promise for significant breakthroughs, but have not been sufficiently advanced or developed to receive support through traditional funding channels.
  • Extension of the current, highly successful stimulus or “seed” grant program to include all gynecologic cancers, and the opportunity for competitive renewals at the conclusion of the one-year research grant.

Deadline continuous

Other Peer Review

None at this time.